Elisabetta Leo
Biomedical Research, Anticancer Drug Development
Elisabetta Leo holds a degree in Pharmaceutical Chemistry and Technology and a PhD in Molecular Pharmacology from Università di Padova. In 2001, she moved to London for her PhD and later a postdoc at University College London. In 2008, she joined the Center for Cancer Research (NCI/NIH) in Bethesda, USA, studying proteins as biomarkers and drug targets in genitourinary and breast cancers, mechanisms of new anticancer drugs, and factors predicting chemotherapy response. In 2012, she moved to the MD Anderson Cancer Center, Houston, focusing on discovering and validating new targets and drugs. In 2015, she returned to the UK, joining a DDU at Cancer Research UK. Since 2016, she has been at AstraZeneca (AZ) in anticancer R&D. She currently serves as Early Development Global Asset Lead for new anticancer drug R&D in a pharmaceutical company in London. Outside work, she enjoys time with loved ones, outdoor sports, discovering new places, and hiking and via ferrata in the Dolomites.
University: Università di Padova, University College London